RIGL

Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03

Figures on this page computed 2026-11-08 12:40 UTC

Last close

51.29USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-03

1.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Against its rival

lens 4 of 9

Measure by measure

behind on 0 of 1

Profit on each unit of salesn/a-678%n/a
Higher is better here.
Return on the capital it usesn/an/an/a
Higher is better here.
Sales growth over five years22.1%-19.0%Ahead
Higher is better here.
Debt against equityn/an/an/a
Lower is better here.
Gross margin93.3%n/an/a
Higher is better here.
Price against earnings1.9xn/an/a
Lower is better here.

The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.

Against Verastem, Inc., RIGL is behind on 0 of 1 measures.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Profit on each unit of salesn/mnet income exceeds revenue
Net income exceeds revenue.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Return on the capital it usesn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Sales growth over five years22.1%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Debt against equityn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Gross margin93.3%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Price against earnings1.9x
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself